Grace Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2024 | — | $61.7M | $23.0M |
| FY2025 | — | $66.6M | $22.1M |
| FY2026 | — | $63.9M | $17.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2024 | — | $61.7M | $23.0M |
| FY2025 | — | $66.6M | $22.1M |
| FY2026 | — | $63.9M | $17.0M |